Burlington Stores Inc vs Neurocrine Biosciences Inc — how do they compare? Burlington Stores Inc trades at $356.12 (market cap $22.59B), while Neurocrine Biosciences Inc trades at $158.2 (market cap $16.46B). The key difference: Burlington Stores Inc is the larger of the two by market cap, and Burlington Stores Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| BURL | NBIX | |
|---|---|---|
Market Cap | $22.59B | $16.46B |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $185.50 |
52-Week Low | $242.43 | $123.10 |
Enterprise Value | $27.71B | $16.48B |
Trailing returns across standard periods
Latest headlines on both assets
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →